However, randomized controlled trials (RCT) are still insufficient.<h4>Methods</h4>This is a prospective, randomized, parallel-group, open-label, superiority-controlled design that evaluates the safety and efficacy of adding tirzepatide to insulin therapy in participants with T1D under automated insulin delivery (AID) control. This evidence concerns the gene INS and type 1 diabetes mellitus.